Overall rank by patents
#13,194
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Twenty Twenty Therapeutics Llc
USPTO PatentsView assignee record - 23 granted patents across 25 technology areas, active 2021–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
23
Total patents granted
25
CPC technology areas
17.3
Avg claims per patent
-
5-year filing velocity
The verdict
Twenty holds 23 US patents across 25 technology areas, rank #13,194 of 50,000 tracked assignees.
- #13,194
- of 50,000 US assignees by volume
- Top 4%
- by Innovation Score (59.0/100)
- 17.3
- avg claims per patent
Portfolio overview
TWENTY TWENTY THERAPEUTICS LLC has been granted 23 US utility patents between 2021 and 2024, placing TWENTY TWENTY THERAPEUTICS LLC at rank #13,194 across all assignees tracked by PlainPatent. This portfolio spans 25 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.3 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, TWENTY TWENTY THERAPEUTICS LLC is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 59.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2024, with 23 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. TWENTY TWENTY THERAPEUTICS LLC's 17.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 25 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark TWENTY TWENTY THERAPEUTICS LLC against peers pursuing similar technology classes.
How does TWENTY compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Twenty Twenty The… ◀ 23
TWENTY TWENTY THERAPEUTICS LLC
23 patents
What this shows TWENTY holds 23 patents, placing it at rank #13,194 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
TWENTY's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
59 Top 4% higher than 96% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2021–2024
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 1 | 4.3% |
| 2022 | 6 | 26.1% |
| 2023 | 8 | 34.8% |
| 2024 | 8 | 34.8% |
Which technologies does TWENTY TWENTY THERAPEUTICS LLC patent most?
Top 15 of 25 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Multi-domain
Claim Depth Standard
Frequently Asked Questions
How many patents does TWENTY TWENTY THERAPEUTICS LLC hold?
TWENTY TWENTY THERAPEUTICS LLC holds 23 US granted patents filed between 2021 and 2024, spanning 25 technology areas.
What is TWENTY TWENTY THERAPEUTICS LLC's Innovation Score?
TWENTY TWENTY THERAPEUTICS LLC has an Innovation Score of 59.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does TWENTY TWENTY THERAPEUTICS LLC focus on?
TWENTY TWENTY THERAPEUTICS LLC's top technology area is A61B (DIAGNOSIS; SURGERY; IDENTIFICATION) with 14 patents. The company has filed patents in 25 CPC subclasses total.
Is TWENTY TWENTY THERAPEUTICS LLC's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for TWENTY TWENTY THERAPEUTICS LLC.
What does claim depth mean for TWENTY TWENTY THERAPEUTICS LLC's patents?
TWENTY TWENTY THERAPEUTICS LLC's patents average 17.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the TWENTY TWENTY THERAPEUTICS LLC patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Twenty's 23 grants land it in the top 4% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Twenty ranks #13,194 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61B - see who else leads that technology area. A61B leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61B technology
TWENTY TWENTY THERAPEUTICS LLC's primary CPC class, all holders and yearly trends
Top 50 patent holders
See where TWENTY TWENTY THERAPEUTICS LLC ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
